Eli Lilly and Company $LLY Shares Sold by Townsquare Capital LLC

Townsquare Capital LLC reduced its stake in Eli Lilly and Company (NYSE:LLY) by 10.9% in the 4th quarter, Holdings Channel reports. The firm owned 5,291 shares of the company’s stock after selling 650 shares during the quarter. Eli Lilly and Company accounts for approximately 1.3% of Townsquare Capital LLC’s portfolio, making the stock its 18th biggest position. Townsquare Capital LLC’s holdings in Eli Lilly and Company were worth $5,686,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of LLY. Brighton Jones LLC grew its stake in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares in the last quarter. Schnieders Capital Management LLC. grew its stake in shares of Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC acquired a new stake in shares of Eli Lilly and Company during the second quarter valued at about $356,000. Finally, Nebula Research & Development LLC acquired a new stake in shares of Eli Lilly and Company during the second quarter valued at about $749,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.5%

NYSE:LLY opened at $1,138.78 on Thursday. The company has a market capitalization of $1.07 trillion, a price-to-earnings ratio of 40.45, a price-to-earnings-growth ratio of 1.25 and a beta of 0.53. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,182.73. The stock has a 50-day simple moving average of $989.96 and a 200 day simple moving average of $1,015.14. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period last year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA approved extended every-8-weeks maintenance dosing for EBGLYSS, improving convenience and potentially boosting adoption in Lilly’s dermatology business.
• Positive Sentiment: Reuters reported that Lilly is still viewed as the leader in the fast-growing obesity-drug market, even as rivals rush into the space, reinforcing confidence in its competitive moat. Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
• Positive Sentiment: Recent coverage also highlighted positive Phase 3 data for retatrutide and favorable Foundayo (orforglipron) weight-loss results, keeping investor enthusiasm high around Lilly’s obesity pipeline.
• Positive Sentiment: Jefferies raised its price target on LLY to $1,350 and reiterated a Buy rating, signaling continued analyst confidence in the stock’s runway. Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw?
• Positive Sentiment: Lilly also announced a new Alzheimer’s collaboration with AlzeCure, expanding its neuroscience pipeline and adding another potential long-term growth opportunity.
• Neutral Sentiment: Several articles were commentary pieces or portfolio lists that reinforce Lilly’s reputation as a high-quality defensive growth name, but they do not add materially new fundamental information.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on LLY shares. Barclays raised their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Jefferies Financial Group raised their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday. Leerink Partners set a $1,119.00 price target on Eli Lilly and Company in a research note on Tuesday, May 26th. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Friday, June 5th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,227.74.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.